Total Payments
$118,419
2024 Payments
$5,033
Companies
62
Transactions
441
Medicare Patients
1,959
Medicare Billing
$415,939
Payment Breakdown by Category
Other$56,600 (47.8%)
Consulting$30,155 (25.5%)
Travel$19,904 (16.8%)
Food & Beverage$11,487 (9.7%)
Education$273.59 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $55,550 | 35 | 46.9% |
| Consulting Fee | $30,155 | 12 | 25.5% |
| Travel and Lodging | $19,904 | 48 | 16.8% |
| Food and Beverage | $11,487 | 326 | 9.7% |
| Honoraria | $1,050 | 1 | 0.9% |
| Education | $273.59 | 19 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $84,608 | 130 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $8,145 | 56 | $0 (2024) |
| Incyte Corporation | $6,900 | 10 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $5,774 | 11 | $0 (2024) |
| PFIZER INC. | $4,788 | 32 | $0 (2024) |
| Globus Medical, Inc. | $1,090 | 2 | $0 (2023) |
| AVEO Pharmaceuticals, Inc. | $1,089 | 4 | $0 (2022) |
| BeiGene USA, Inc. | $525.00 | 1 | $0 (2022) |
| Celgene Corporation | $446.37 | 29 | $0 (2024) |
| Gilead Sciences, Inc. | $397.32 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,033 | 17 | Incyte Corporation ($2,580) |
| 2023 | $8,107 | 52 | Incyte Corporation ($3,959) |
| 2022 | $8,912 | 62 | AstraZeneca Pharmaceuticals LP ($6,194) |
| 2021 | $1,454 | 43 | AstraZeneca Pharmaceuticals LP ($700.00) |
| 2020 | $5,001 | 50 | AstraZeneca Pharmaceuticals LP ($4,245) |
| 2019 | $24,972 | 79 | AstraZeneca Pharmaceuticals LP ($23,423) |
| 2018 | $32,509 | 68 | AstraZeneca Pharmaceuticals LP ($26,431) |
| 2017 | $32,431 | 70 | AstraZeneca Pharmaceuticals LP ($21,398) |
All Payment Transactions
441 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $138.16 | General |
| Category: ONC | ||||||
| 04/23/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $104.29 | General |
| 04/06/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $2,580.00 | General |
| 03/19/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $19.65 | General |
| Category: ONCOLOGY | ||||||
| 03/07/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $1,837.50 | General |
| Category: Oncology | ||||||
| 03/07/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $139.06 | General |
| 03/05/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $21.66 | General |
| Category: Oncology | ||||||
| 02/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $19.92 | General |
| Category: Hematology | ||||||
| 02/21/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, COMIRNATY | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: ONCOLOGY | ||||||
| 02/13/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $26.53 | General |
| 02/06/2024 | Bausch Health US, LLC | APLENZIN (Drug) | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: Neurology | ||||||
| 02/01/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: Oncology | ||||||
| 01/25/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: Oncology | ||||||
| 01/18/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug), PLUVICTO | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Oncology | ||||||
| 01/12/2024 | Menarini Silicon Biosystems, Inc. | Cellsearch (Device) | Food and Beverage | Cash or cash equivalent | $21.12 | General |
| Category: Diagnostics | ||||||
| 01/09/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Oncology | ||||||
| 12/21/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.16 | General |
| 12/12/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: Cancer | ||||||
| 12/11/2023 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.49 | General |
| Category: Oncology | ||||||
| 11/07/2023 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: BioOncology | ||||||
| 11/02/2023 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: ONCOLOGY | ||||||
| 10/26/2023 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 446 | 994 | $239,303 | $93,185 |
| 2022 | 8 | 482 | 1,216 | $286,033 | $110,821 |
| 2021 | 8 | 509 | 1,177 | $265,624 | $107,271 |
| 2020 | 8 | 522 | 1,262 | $292,437 | $104,661 |
Total Patients
1,959
Total Services
4,649
Medicare Billing
$415,939
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 233 | 746 | $166,358 | $65,772 | 39.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 50 | 50 | $21,300 | $8,098 | 38.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 39 | 51 | $15,249 | $6,735 | 44.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 69 | 88 | $13,376 | $5,125 | 38.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 34 | 38 | $15,922 | $5,068 | 31.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $7,098 | $2,387 | 33.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 228 | 889 | $196,443 | $76,672 | 39.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 44 | 81 | $24,063 | $10,586 | 44.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 49 | 49 | $20,754 | $7,886 | 38.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 81 | 101 | $15,190 | $5,323 | 35.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 26 | 31 | $12,989 | $4,689 | 36.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $7,744 | $2,565 | 33.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 17 | 18 | $5,130 | $1,793 | 35.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 24 | $3,720 | $1,307 | 35.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 224 | 810 | $177,390 | $72,560 | 40.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 120 | 155 | $23,095 | $9,208 | 39.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 40 | 59 | $17,405 | $8,168 | 46.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 48 | 48 | $20,208 | $7,414 | 36.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 19 | $7,941 | $2,939 | 37.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 19 | 24 | $6,807 | $2,521 | 37.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 22 | 44 | $6,748 | $2,443 | 36.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 18 | 18 | $6,030 | $2,018 | 33.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 232 | 870 | $188,380 | $67,535 | 35.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 59 | 116 | $34,220 | $12,048 | 35.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 57 | 57 | $23,997 | $8,476 | 35.3% |
About Dr. Muhammad Mirza, M.D
Dr. Muhammad Mirza, M.D is a Hematology & Oncology healthcare provider based in Washington, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568561678.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Muhammad Mirza, M.D has received a total of $118,419 in payments from pharmaceutical and medical device companies, with $5,033 received in 2024. These payments were reported across 441 transactions from 62 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($55,550).
As a Medicare-enrolled provider, Mirza has provided services to 1,959 Medicare beneficiaries, totaling 4,649 services with total Medicare billing of $415,939. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Washington, MO
- Active Since 09/22/2006
- Last Updated 08/06/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1568561678
Products in Payments
- TAGRISSO (Drug) $54,969
- IMFINZI (Drug) $24,585
- Non-Covered $5,741
- MEKINIST (Drug) $5,581
- XALKORI (Drug) $4,480
- IMFINZI (Biological) $3,448
- KISQALI (Drug) $2,050
- FOTIVDA (Drug) $1,089
- Excelsius3D Imaging System (Device) $738.50
- BRUKINSA (Drug) $525.00
- ExcelsiusGPS Robotic Navigation System (Device) $351.64
- Doptelet (Drug) $250.37
- KEYTRUDA (Biological) $192.55
- LATUDA (Drug) $191.60
- Trodelvy (Drug) $166.52
- IBRANCE (Drug) $165.39
- VYXEOS (Drug) $157.87
- OPDIVO (Biological) $146.60
- clonoSEQ (Device) $145.02
- CALQUENCE (Drug) $144.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Washington
Imad Tabbara, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
John Marshall
Hematology & Oncology — Payments: $770,250
Hematology & Oncology $770,250
Dr. Catherine Broome, Md, MD
Hematology & Oncology — Payments: $693,161
Hematology & Oncology $693,161
Craig Kessler
Hematology & Oncology — Payments: $632,186
Hematology & Oncology $632,186
Claudine Isaacs
Hematology & Oncology — Payments: $406,847
Hematology & Oncology $406,847
Dr. Christopher Gallagher, M.d, M.D
Hematology & Oncology — Payments: $107,252
Hematology & Oncology $107,252